FeesSafety
Pluang+

Cytokinetics grants stock options and RSUs to new employees as inducements under Nasdaq rules.

Company Fundamentals
16 Nov 2026, 23:00 WIB
GlobeNewsWire
View Source
Neutral
Cytokinetics grants stock options and RSUs to new employees as inducements under Nasdaq rules.

Cytokinetics granted stock options for 64,110 shares and 42,496 restricted stock units (RSUs) to 18 new employees who started in October and November 2026. The RSUs vest over three years, while the stock options vest over four years with a $56.13 exercise price, matching the stock's closing price on November 13, 2026. These grants are inducements to employment under Nasdaq Listing Rule 5635(c)(4). Cytokinetics is a biopharmaceutical company focused on cardiac muscle diseases, advancing treatments like MYQORZO® and other investigational drugs. This move supports talent acquisition as the company progresses in its drug development pipeline.

Cytokinetics Inc (CYTK) shares trade at USD 53.35 on Pluang as of Nov 17, 2026 04:12 WIB. The stock is down 4.95% for the day with a market cap of $7.81B. Investors typically hold CYTK for about 21 days on Pluang.

More News (CYTK)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App